ArticleJournal of experimental & clinical cancer research : CR2025
LL22NC03-N14H11.1 regulates the m6A modification of MYC and promotes glycolytic activity in hepatocellular carcinoma cells by inhibiting IGF2BP3 ubiquitination degradation.
Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The lncRNA-m6A axis in cancer: a bidirectional regulatory network in tumor progression and therapeutic resistance.Journal of translational medicine · 2026Review
- IGF2BP3 promotes glycolysis of osteosarcoma stem cells by reading RNA m⁶A to stabilize ENO1 and promote malignant biological behavior of osteosarcoma.Cell biology and toxicology · 2026Article
- Article
- VASN Enhances IGF2BP3 Stability via USP10 Deubiquitination to Promote Triple-negative Breast Cancer Paclitaxel Resistance.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is the fifth leading cause of cancer-related mortality globally. Long non-coding RNAs (lncRNAs) are increasingly recognized for their pivotal roles in hepatocarcinogenesis. Specifically, the lncRNA LL22NC03-N14H11.1 (hereafter referred to as LL22NC03) has been characterized as a potent oncogenic factor in certain cancers. Therefore, our research aimed to investigate the involvement of LL22NC03 in HCC progression.
methodsWe analyzed the expression of IGF2BP3 in HCC specimens obtained from The Cancer Genome Atlas (TCGA) dataset. Further investigation via RNA pull-down and mass spectrometry analysis identified LL22NC03 as a binding partner of IGF2BP3, with LL22NC03 enhancing the stability of IGF2BP3 by inhibiting TRIM25-mediated ubiquitination. Subsequent in vitro and in vivo experiments were conducted to explore the modulation of LL22NC03 expression, in combination with manipulation of IGF2BP3 levels, which significantly impacted glycolysis, proliferation, migration, and invasiveness of HCC cells.
resultsThe study identified LL22NC03 as a promoter of HCC proliferation and migration of HCC cells. LL22NC03 was observed to bind to the ubiquitination site of IGF2BP3, thereby preventing its degradation and enhancing its stability. This interaction ultimately inhibited the degradation of IGF2BP3. Additionally, the interaction between LL22NC03 and IGF2BP3 facilitated the transcription of MYC, leading to the upregulation of glycolytic genes, including HK2, LDHA, GLUT1, PKM2, and PDK1. Finally, IGF2BP3 played a role in stabilizing MYC by recognizing N6-methyladenosine (m6A) modifications.
conclusionThe LL22NC03-IGF2BP3-MYC regulatory axis is critically involved in the progression of HCC, suggesting its potential as a novel therapeutic target for this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.